Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Windtree Therapeutics, Inc./ 424B3

SEC Filing · 424B3

Windtree Therapeutics, Inc.

WINTOTCEQUITYCurrent

SEC Filing

Filed Nov 13, 2025Accepted Nov 13, 2025, 3:01 AM ESTCIK 946486Accession 0001437749-25-034620
View company →Permanent SEC source ↗
Share

Company context

We are a diversified company with several divisions and focused on seeking partnerships and becoming a revenue-generating company through various initiatives. Our operations include pharmaceutical manufacturing as a sourcing agent for Evofem Biosciences, Inc. (“Evofem”), and biotechnology.

Current securities

WINTOTC · EQUITY · Current
Historical securities (7)
WINTNASDAQ · EQUITY · Historical · closed Aug 20, 2025WINTOTC · EQUITY · Historical · closed Dec 22, 2017WINTOTC · EQUITY · Historical · closed Apr 29, 2020WINTOTC · EQUITY · Historical · closed Dec 22, 2017WINTDOTC · EQUITY · Historical · closed Jan 22, 2018WINTDOTC · EQUITY · Historical · closed May 20, 2020WINTWOTC · WARRANT · Historical · closed Mar 25, 2026

Recent company filings

  1. Entry into a Material Definitive AgreementJul 22, 2026
  2. NT 10-K filingApr 1, 2026
  3. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsJan 7, 2026
  4. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity SecuritiesDec 2, 2025
  5. 424B3 filingNov 21, 2025

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.